携带非典型BCR-ABL1转录本的慢性髓性白血病的无治疗缓解 - Suppr

Treatment-Free Remission in Chronic Myeloid Leukemia Harboring Atypical BCR-ABL1 Transcripts.

作者信息

Dragani Matteo, Petiti Jessica, Rege-Cambrin Giovanna, Gottardi Enrico, Daraio Filomena, Caocci Giovanni, Aguzzi Chiara, Crisà Elena, Andreani Giacomo, Caciolli Francesca, Fava Carmen

机构信息

Department of Clinical and Biological Sciences, University of Turin, Orbassano.

Department of Hematology, University of Cagliari, Cagliari.

出版信息

Mediterr J Hematol Infect Dis. 2020 Sep 1;12(1):e2020066. doi: 10.4084/MJHID.2020.066. eCollection 2020.

DOI:10.4084/MJHID.2020.066

PMID:32952977

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7485467/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3b7/7485467/91fd00f11f7d/mjhid-12-1-e2020066f1.jpg

相似文献

Treatment-Free Remission in Chronic Myeloid Leukemia Harboring Atypical BCR-ABL1 Transcripts.

Mediterr J Hematol Infect Dis. 2020 Sep 1;12(1):e2020066. doi: 10.4084/MJHID.2020.066. eCollection 2020.

Novel Multiplex Droplet Digital PCR Assays to Monitor Minimal Residual Disease in Chronic Myeloid Leukemia Patients Showing Atypical Transcripts.

J Clin Med. 2020 May 13;9(5):1457. doi: 10.3390/jcm9051457.

A rare BCR-ABL1 transcript in Philadelphia-positive acute myeloid leukemia: case report and literature review.

BMC Cancer. 2019 Jan 10;19(1):50. doi: 10.1186/s12885-019-5265-5.

Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients.

Int J Lab Hematol. 2017 Jun;39(3):235-242. doi: 10.1111/ijlh.12616. Epub 2016 Dec 29.

Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells.

Leukemia. 2018 Dec;32(12):2572-2579. doi: 10.1038/s41375-018-0264-0. Epub 2018 Oct 12.

Considerations for Successful Treatment-free Remission in Chronic Myeloid Leukemia.

Clin Lymphoma Myeloma Leuk. 2018 Feb;18(2):98-105. doi: 10.1016/j.clml.2017.11.006. Epub 2017 Nov 29.

Rapid decline of Philadelphia-positive metaphases after nilotinib treatment in a CML patient expressing a rare e14a3 fusion transcript: A case report.

Oncol Lett. 2019 Sep;18(3):2648-2653. doi: 10.3892/ol.2019.10558. Epub 2019 Jul 4.

A rare e13a3 (b2a3) BCR-ABL1 fusion transcript with normal karyotype in chronic myeloid leukemia: The challenges in diagnosis and monitoring minimal residual disease (MRD).

Leuk Res. 2017 Aug;59:8-11. doi: 10.1016/j.leukres.2017.05.009. Epub 2017 May 12.

Chronic Myeloid Leukemia with an e6a2 Fusion Transcript: Cooperating Mutations at Blast Crisis and Molecular Monitoring.

Case Rep Hematol. 2017;2017:9071702. doi: 10.1155/2017/9071702. Epub 2017 Oct 16.

A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib.

PLoS One. 2019 Mar 5;14(3):e0207170. doi: 10.1371/journal.pone.0207170. eCollection 2019.

引用本文的文献

Exploration of treatment-free remission in CML, based on molecular monitoring.

Cancer Med. 2024 Jan;13(1):e6849. doi: 10.1002/cam4.6849. Epub 2023 Dec 22.

Brazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practice.

Hematol Transfus Cell Ther. 2022 Jul-Sep;44(3):402-409. doi: 10.1016/j.htct.2022.04.002. Epub 2022 May 3.

Genomic Mechanisms Influencing Outcome in Chronic Myeloid Leukemia.

Cancers (Basel). 2022 Jan 26;14(3):620. doi: 10.3390/cancers14030620.

Discontinuation of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia: a Review of the Biological Factors Associated with Treatment-Free Remission.

Curr Oncol Rep. 2022 Apr;24(4):415-426. doi: 10.1007/s11912-022-01228-w. Epub 2022 Feb 10.

Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools.

Target Oncol. 2021 Nov;16(6):823-838. doi: 10.1007/s11523-021-00831-4. Epub 2021 Oct 18.

Standardization of BCR-ABL1 p210 Monitoring: From Nested to Digital PCR.

Cancers (Basel). 2020 Nov 6;12(11):3287. doi: 10.3390/cancers12113287.

Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia.

Front Oncol. 2020 Jun 2;10:883. doi: 10.3389/fonc.2020.00883. eCollection 2020.

本文引用的文献

Novel Multiplex Droplet Digital PCR Assays to Monitor Minimal Residual Disease in Chronic Myeloid Leukemia Patients Showing Atypical Transcripts.

J Clin Med. 2020 May 13;9(5):1457. doi: 10.3390/jcm9051457.

Comparison of Real-Time Quantitative PCR and Digital Droplet PCR for BCR-ABL1 Monitoring in Patients with Chronic Myeloid Leukemia.

J Mol Diagn. 2020 Jan;22(1):81-89. doi: 10.1016/j.jmoldx.2019.08.007. Epub 2019 Oct 24.

Performance Evaluation of the QXDx BCR-ABL %IS Droplet Digital PCR Assay.

Ann Lab Med. 2020 Jan;40(1):72-75. doi: 10.3343/alm.2020.40.1.72.

"Variant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay." Is dPCR the key?

Eur J Haematol. 2019 Sep;103(3):272-273. doi: 10.1111/ejh.13282. Epub 2019 Jul 7.

The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview.

Leukemia. 2019 May;33(5):1173-1183. doi: 10.1038/s41375-018-0341-4. Epub 2019 Jan 23.

Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology.

J Natl Compr Canc Netw. 2018 Sep;16(9):1108-1135. doi: 10.6004/jnccn.2018.0071.

Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2017 Jul 1;28(suppl_4):iv41-iv51. doi: 10.1093/annonc/mdx219.

Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib.

Clin Lymphoma Myeloma Leuk. 2017 Nov;17(11):728-733. doi: 10.1016/j.clml.2017.06.009. Epub 2017 Jun 21.

The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.

Am J Hematol. 2017 Aug;92(8):797-805. doi: 10.1002/ajh.24774. Epub 2017 May 30.

No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib.

J Cancer Res Clin Oncol. 2017 May;143(5):843-850. doi: 10.1007/s00432-016-2321-2. Epub 2017 Jan 12.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Treatment-Free Remission in Chronic Myeloid Leukemia Harboring Atypical BCR-ABL1 Transcripts.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献